Multiparametric magnetic resonance in the assessment of the gender differences in a high-grade glioma rat model by Pérez-Carro, Rocío et al.
Pérez-Carro et al. EJNMMI Research 2014, 4:44
http://www.ejnmmires.com/content/4/1/44ORIGINAL RESEARCH Open AccessMultiparametric magnetic resonance in the
assessment of the gender differences in a
high-grade glioma rat model
Rocío Pérez-Carro1, Omar Cauli2 and Pilar López-Larrubia1*Abstract
Background: Glioblastoma, the most frequent and aggressive of all astrocytomas, presents a clear predominance in
male humans, but the assessment of sexual differences in its tumourigenesis and growth has received little
attention so far. In this study, we aim to identify gender-dependent surrogate markers in an animal model of this
cancer by means of magnetic resonance (MR) imaging and biochemical and behavioural studies.
Methods: A high-grade glioma model developed in male and female rats was used. Multiparametric magnetic
resonance images and localized spectra were acquired. The MR parameters linked to tumoural features were quantified.
Motor and metabolic activity was also assessed. Postmortem analyses were carried out to measure indicators of
malignancy, tumoural metabolism and viability of the blood-brain barrier (BBB).
Results: Statistically significant differences dependent on the animal sex were found in the study of pathological
indicators like oedema, inflammation, cellularity and microvasculature. Results suggest higher cell proliferative rate,
inflammation and vasogenic oedema and or necrosis in glioma-bearing male rats. Haemodynamic parameters measured
indicated a major disruption of the BBB, postmortem confirmed, in this sex. Metabolomic and energetic metabolism
activity data are in agreement with a major malignancy and aggressiveness of this cancer model on males.
Conclusions: Gender differences should be taken into account in preclinical studies of glioblastoma models, in the
characterization of the tumoural behaviour and consequently in the development and validation of new therapeutic
approaches. MR imaging and spectroscopy allow to non-invasively monitor this sexual dimorphism in the diagnosis and
prognosis of brain cancer.
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Gender-dependent markersBackground
Despite decades of intensive research, high-grade gliomas
(WHO grade III and IV) [1] are currently considered
incurable with a poor or very poor survival. The mean
survival for these tumours remains, on average, 1 year for
glioblastoma patients and from 2 to 3 years for anaplastic
astrocytoma after diagnosis [2]. Glioblastoma multiforme
(GBM) is the most frequent, aggressive and lethal intra-
cranial tumour, accounting for approximately 50% of all
astrocytomas [3]. This glioma is defined by a marked* Correspondence: plopez@iib.uam.es
1Laboratory of Magnetic Resonance in the Study of the Central Nervous
System, Instituto de Investigaciones Biomédicas ‘Alberto Sols’, CSIC-UAM,
Arturo Duperier 4, 28029 Madrid, Spain
Full list of author information is available at the end of the article
© 2014 Pérez-Carro et al.; licensee Springer. Th
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origgenetic instability, complete morphological and metabolic
reprogramming, fast and uncontrolled proliferation, in-
tense resistance to apoptosis, diffuse infiltration, robust
angiogenesis and propensity to necrosis. Despite advances
in multimodal therapeutic options [4], the median survival
after diagnosis of GBM is only 14.6 months [5].
Despite the clear predominance of GBM tumours in the
male population, the impact of these differences in brain
tumourigenesis has received little attention to date. Par-
ticularly, there is a lack of gender-based studies with
regard to brain tumour evolution and response to treat-
ment. McKinley et al. reported in 2000 that males are 1.5
to 2 times more likely to develop glioblastoma compared
with females [6]. Later, based on epidemiological datais is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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described a clear predominance of brain tumours in
males compared to females with a ratio ranging from
>1 to 3.5 [7]. They indicated that sex affects brain
tumourigenesis through mechanisms that are likely to
be independent of race and regional differences in
environmental exposures. The same study established
that the influence of gender on brain tumourigenesis is
operative regardless/independent of age and sexual
maturity, suggesting that it is not a consequence of the
acute effects of circulating sex hormones. Interestingly,
a positive association between late menarche and in-
creased risk of glioma has been reported [8,9]. Further-
more, experimental studies show that oestrogens and
their modulators inhibit proliferation of gliomas in vivo
and induce cell death [10-13]. All these works suggest
that genetic differences between males and females may
play a role in the pathogenesis of this tumour. There-
fore, the molecular mechanisms responsible for the de-
velopment of gliomas in the different genders should be
further evaluated. These studies could have a significant
impact on our understanding of brain tumourigenesis
and on therapeutic stratification.
Nowadays, magnetic resonance imaging (MRI) plays a
key role in the detection, staging, characterization of the
tumour infiltration and therapy validation of gliomas
[14-16]. MRI techniques are commonly used to measure
brain tumour growth, vasculature, biochemical metabol-
ism and molecular changes in both human and preclin-
ical models [15], representing the main imaging tool
used in the diagnosis of gliomas [17]. However, conven-
tional MRI of gliomas has inherent limitations, such as
inadequate assessment of both peritumoural oedema
and integrity of the adjacent white matter [18,19]. The
use of conventional paramagnetic or superparamagnetic
contrast media allows the identification of areas with
blood-brain barrier (BBB) disruption [20]. In addition,
the recent molecular imaging approaches enable re-
searchers to visualize molecular events associated with
tumour proliferation and invasion, bringing the potential
of diagnostic imaging to the cellular and molecular as-
pects of tumour biology [21]. Advanced magnetic reson-
ance imaging techniques such as diffusion-weighted
(DWI) and perfusion-weighted imaging (PWI) methods
can provide useful information on tumour location and
extent of growth, brain invasiveness, regional blood
flow and blood volume, inflammation and tumour
cellularity. All of these tumour features/characteristics
are specific for different glioma grades and can offer an
invaluable help in patient prognosis [20,22,23]. More-
over, magnetization transfer (MT) imaging is believed
to provide a non-specific indicator of the structural in-
tegrity of the tissue, being different in tumours com-
pared with healthy tissue because of the inflammatoryprocesses that take place in the lesion [24]. Finally,
magnetic resonance spectroscopy (MRS) offers the pos-
sibility of obtaining in vivo information about tumoural
metabolism, identifying the metabolites that better cor-
relate with neoplastic progression [25].
As far as we know, MRI and MRS have not been used
to study either gender differences in brain tumourigenesis
or to assess differences in the tumoural microenvironment
characterization depending on the sex. The last objective
of this work is to estimate whether gender differences
could play a role in the biology and aggressiveness of
glioblastoma multiforme. The C6 glioma rat was used as
an experimental model of GBM to test differences in
tumour growth and invasion [26], and tumour features
like cellularity, oedema, necrosis, macromolecular envir-
onment, haemodynamic parameters and metabolism were
evaluated by in vivo MR techniques. Metabolic behaviour
was also analysed by placing rats in automated behav-
ioural monitoring home cages [27]. Finally, postmortem
BBB permeability was assessed by measuring extravasation
of Evans blue-albumin [28] and glutamate and glutamine
by high-performance liquid chromatography (HPLC). The
putative glioblastoma biomarker glial fibrillary acidic
protein (GFAP) [29] was also measured in the blood
serum.
Methods
Animal handling
The experimental procedures were approved by the ethical
committee of our centre (Instituto de Investigaciones
Biomédicas ‘Alberto Sols’) and met the national (R.D. 53/
2013) and the European Community guidelines (2010/62/
UE) for care and management of experimental animals.
The rats were housed in the animal premises of our insti-
tution (Reg. No. ES280790000188) and cared by specialized
personnel.
Albino Wistar rats (Rattus norvegicus) were used
(body weight (b.w.) 230 ± 20 g). The animals were kept
in cages in a controlled room, with a 12-h cycle of light
and darkness, temperature of 22°C ± 2°C and water and
food access ad libitum. Four different groups of animals
(n = 8 rats per group) were employed, two of them con-
stituted tumour-bearing rats divided in two sub-groups
of male and female individuals, and the other two were
sham groups of male and females also. An additional
cohort of 20 rats grouped in the same four experimental
conditions (n = 5) was used to measure spontaneous
energy metabolism parameters and to perform postmor-
tem analysis by duplicate.
Tumour implantation
Authenticated rat glioma C6 cells were obtained from
the American Type Culture Collection (ATCC number
CCL-107) (Manassas, VA, USA). The cells were grown
Pérez-Carro et al. EJNMMI Research 2014, 4:44 Page 3 of 13
http://www.ejnmmires.com/content/4/1/44in Dulbecco's modified eagle medium-4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (DMEM-HEPES) to which
10% fetal bovine serum (FBS) (Gibco®, Thermo Fisher
Scientific, Inc., Waltham, MA, USA) and antibiotics were
added. The animals were intraperitoneally (i.p.) anaesthe-
tized (with a mixture of ketamine hydrochloride (75 mg/kg
b.w.) and medetomidine hydrochloride (0.5 mg/kg b.w.))
and placed in a stereotaxic device where 105 C6 cells in
10 μL of medium were injected in the right caudate nu-
cleus [30]. After surgery, the rats were induced to recover
with atipamezole hydrochloride (5 mg/kg b.w.) adminis-
trated subcutaneously (s.c.). They also received meloxicam
s.c. as analgesia (0.5 mg/kg b.w.) during the following
3 days. Sham animals were submitted to the same proced-
ure with an intracranial injection of 10 μL of DMEM-
HEPES alone.Magnetic resonance experiments
In vivo MR experiments were performed on a Bruker
Pharmascan system (Bruker Medical GmbH®, Ettlingen,
Germany) using a 7.0-T horizontal superconducting
magnet, equipped with a 38-mm diameter 1H selective
birdcage resonator and a gradient insert with 90-mm
diameter and a maximum intensity of 360 mT/m. All
data were acquired by running the ParaVision 5.1. soft-
ware (Bruker Medical Gmbh®) operating on a Linux plat-
form. Anaesthesia was initiated in an induction box
through inhalation of oxygen (1 L/min) containing 3% to
4% of isofluorane and maintained during the experiment
by employing a nose mask with a flow of 1% to 1.5% of
isofluorane in O2. The animals were placed in a heated
probe, which maintained the core body temperature at
approximately 37°C. The physiological status of the rats
was monitored by a gating system designed for small an-
imals (SA Instruments, Inc., Stony Brook, NY, USA)
using the respiratory rate and body temperature.Anatomical images
T2-weighted (T2W) spin-echo (SE) images were obtained
with a rapid acquisition with relaxation enhancement
(RARE) sequence and the following parameters: repetition
time (TR) = 3,000 ms, echo time (TE) = 60 ms, averages
(Av) = 3 and RARE factor = 8. Contrast-enhanced T1-
weighted (CE-T1W) SE images after i.v. administration of
0.3 M Gd-diethylene triamine pentaacetic acid (DTPA)
(from Magnevist®, Bayer, Whippany NJ, USA), at a dose of
0.3 mmol/kg b.w., were acquired using TR = 300 ms, TE =
10 ms and Av = 3. Also, the T2W and T1W images were
acquired with the geometry parameters: acquisition matrix
(Mtx) = 256 × 256, field of view (FOV) = 3.5 × 3.5 cm2 cor-
responding to an in-plane resolution of 136 × 136 μm2,
slice thickness = 1.5 mm and five slices in axial orientation.Magnetization transfer contrast imaging
Magnetization transfer ratio (MTR) maps were generated
from two equivalent sets of images using TR = 2,500 ms,
TE = 10 ms, Av = 1 and Mtx = 128 × 128 that yielded an
in-plane resolution of 273 × 273 μm2. The imaging set ac-
quired with an MT pulse turn on employs a radiofre-
quency pulse train (N = 50) of bandwidth = 550 Hz,
length = 5 ms, power = 5.5 μT and offset = 1,500 Hz. The
MT effect was calculated according to Equation 1:
%MTR ¼ S0−SMT
S0
 100; ð1Þ
where SMT is the signal intensity of a pixel in the image
with the application of the MT pulses, and S0 is the sig-
nal of the same pixel without it.
Diffusion tensor imaging
Diffusion studies were performed by running a Stejskal-
Tanner sequence with a single-shot echo-planar (ss-EPI)
readout gradient, where TR = 3,000 ms, TE = 40 ms, Av =
1, Mtx = 128 × 128 with an in-plane resolution of 273 ×
273 μm2, diffusion gradient separation (Δ) = 16 ms, diffu-
sion gradient duration (δ) = 4 ms, one basal image (with-
out diffusion gradient application) and two b factors of
300 and 1,400 s/mm2, corresponding to a diffusion gradi-
ent strength of 33% and 71%, respectively, applied in seven
directions. The mean diffusivity (MD) and fractional an-
isotropy (FA) parameters were measured according to
Equations 2 and 3, where the corresponding eigenvalues
(λ1, λ2, λ3) were obtained by solving the tensor.
MD ¼ λ1þ λ2þ λ2
3
ð2Þ
FA ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
λ1 −MDð Þ2 þ λ2−MDð Þ2 þ λ3−MDð Þ2
q
2 λ12 þ λ22 þ λ32ð Þ ð3Þ
Perfusion-weighted imaging
Cerebral perfusion acquisitions were carried out with the
bolus tracking technique [31] using a ss-EPI sequence and
a 0.3 M Gd-DTPA solution. Briefly, the contrast agent
was injected in the dorsal vein of the tail as a bolus
(0.3 mmol/kg b.w.) 10 s after the acquisition start point,
with TR = 250 ms, TE = 7.1 ms, Av = 1, flip angle = 30°
and 150 repetitions that drove a total acquisition time of
38 s. The in-plane resolution was 437 × 547 μm2 from a
Mtx = 80 × 64. Pixel time-evolution signal intensities were
fitted to the appropriate equations for computing the cor-
responding parametric images of cerebral blood volume
(CBV), cerebral blood flow (CBF) and mean transit time
(MTT) as we previously reported [32].
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A point-resolved spatial spectroscopy (PRESS) was
employed, in combination with VAPOR water suppres-
sion protocol, to acquire the spectrum of a 27-
mm3 voxel placed in the tumour (or analogous region in
the control animals) using TR = 3,000 ms, TE = 35 ms
and 128 number of scans. The spectra were processed
with LCModel [33], a prior knowledge spectral fit soft-
ware, and only the peak concentrations obtained with a
standard deviation lower than 20% were accepted.
The animals were checked in the MRI system every 3
to 5 days after intracranial surgery to monitor the
tumour development. All rats were subjected to the
whole MR in vivo protocol described above between 16
to 20 days after intracranial injection of C6 cells (or
DMEM), when the tumour volume reached approxi-
mately 75 to 100 mm3 (measured in CE-T1W images).
Imaging process and analysis
The five slices acquired in every case were computed
with a homemade software (My Map Analyzer) written
in MatLab v. 7.01 (MathWorks, Nattick, MA, USA) in
which colour-based maps were generated by fitting the
signal intensities to the appropriate equation in a pixel-
by-pixel base. Two regions of interest (ROIs) placed in
the core and in the periphery (enhanced outer ring in
CE-T1W images) of the tumour were manually selected
from parametric maps in glioma-bearing rats. In the
sham animals, analogous ROIs were measured in similar
cerebral areas. The obtained data were analysed with
ImageJ (National Institutes of Health, Bethesda, MD,
USA, http://rsbweb.nih.gov/ij/). For the different mea-
sured parameters, the data are presented in terms of per-
centage, either increased or decreased. The different
values are based on the fact that the analysed brain re-
gion is exactly the same for both glioma rats and control
rats, according to the general expression:
%ΔData ¼ Dataglioma−Datasham
Datasham
 100 ð4Þ
In the perfusion maps, the whole tumour was
analysed. Considering the low resolution of these
images, a clear discrimination between the core and the
periphery of the lesion was not possible.
Metabolic activity analysis
Five animals of each experimental group were studied in a
metabolic and motor analysis system (Phenomaster®, TSE
Systems GmbH, Bad Homburg vor der Höhe, Germany).
The rats were isolated in individual cages where the drink-
ing and feeding behaviour and the spontaneous respira-
tory and motor activities were measured using high-
precision sensors that store the data every 30 min. Toensure a proper acclimation to the modified environment
before the measurements, all rats were placed in training
cages (equipped with the drinking and feeding devices of
the metabolic ones) 24 h prior to measurements [34].
After the training, the animals were moved to the system
and parameters were collected for 60 h. System delivery
also included evaluations of indirect calorimetry via the
respiratory exchange rate (RER), which is the ratio
between delivered CO2 and consumed O2, and provided
information on the metabolic substrate used [27,34].
Postmortem analyses
Once the animals were removed from the analysis sys-
tem, the blood samples were collected from a tail vein
(approximately 1 mL) to isolate blood serum. The rats
were then infused through the right jugular vein at a rate
of 3 mL/min, first with Ringer medium and FBS (18 g/L)
for 3 min; then with a mixture of Ringer, FBS (18 g/L)
and Evans blue (1 g/L) for another 3 min; and finally,
3 min with the same initial mixture of Ringer and FBS
for rinsing. After sacrifice by decapitation, the tumour
and a similar-sized region from the same brain area in
the sham animals were excised. The tissues were kept
frozen at −80°C until their posterior analysis.
Glutamate, glutamine and GFAP determination
The tissue was powdered and deproteinized in perchloric
acid-ethanol mixture [35], and glutamine (Gln) and glu-
tamate (Glu) levels were measured by high-performance
liquid chromatography (HPLC) after derivatization with o-
phthalaldehyde. GFAP was measured in serum by an
ELISA kit (Chemicon, Millipore Co., Billerica, MA, USA),
with the assay sensitivity being 1.5 ng/mL.
BBB permeability determination
Blood-brain barrier permeability was assessed by measur-
ing extravasation of Evans blue-albumin [28]. Frozen brain
tissues were weighted and homogenized in fivefold
volume of 50% trichloroacetic acid solution. The super-
natant was obtained by centrifugation (10 min, 10,000×g,
at 4°C). Evans blue extravasation was quantified in the
supernatants by measuring the fluorescence (excitation at
620 nm and emission at 680 nm) [36].
Statistical analysis
MRI data were obtained from the parametric maps. All
pixels were measured in the same brain region and at
the same experimental condition. Values are presented
as mean ± standard error of the mean (SEM), in both
the absolute and the relative data. Statistical analyses
were performed using GraphPad Prism 4 software
(GraphPad Software, Inc., San Diego, CA, USA); the dif-
ferences were determined by unpaired two-tail t test
analysis with Welch's correction. In all cases, P values
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significant.
Results
MRI and MRS experiments
Magnetization transfer studies measure the distribution
of water molecules in the healthy and diseased brain,
giving information about the brain macromolecular
microenvironment. Results from MT studies in our ex-
perimental conditions are presented in Figure 1.
We found significant differences in the MTR values of
glioma-bearing rats when compared to control animals
in both regions analysed. Also, in male and female rats,
there was an increase in the MTR values obtained in the
periphery of the tumour, while a notable decrease was
measured in the core. There was no difference between
the genders regarding the MTR values in the tumoural
core (−29.45% ± 0.74% for males, −29.90% ± 0.35% for
females). However, a higher MTR value was seen in the
periphery of tumours in males when compared to the fe-
male rats (9.44% ± 0.42% vs 8.09% ± 0.41%, P < 0.05).
Diffusion studies also provide parameters related with
the structure and even the functionality of the brain
[37]. Mean diffusivity measured the higher or lower
water molecule restriction to the transversal motion in
the tissues. Figure 2A shows the MD obtained results forFigure 1 Results from magnetization transfer in the study of
gender influence in a glioblastoma rat model. Graphic shows
variation of MTR values, as a percentage, assessed in two brain
regions (core and periphery of the tumour) of pathological rats
related to the equivalent ones in sham animals. Unpaired t test
analysis was performed on the data by comparing both genders in
the same area. Statistically significant differences are indicated in the
columns, where *P < 0.05.both genders and two regions. Significant statistical
differences were found comparing both tumoural
areas, where an increase took place in the core but a
decrease in the periphery. The Δ MD detected in the
glioma rats in relation to the control ones was higher
for males than for females both in the core (Δ MD:
16.77% ± 0.34% vs. 13.37% ± 0.22%, P < 0.001) and in
the periphery of the tumour (Δ MD: −6.59% ± 0.22%
vs. −5.03% ± 0.28%, P < 0.05).
In addition, fractional anisotropy maps give a value
that directly correlates with the microstructure
organization of the brain tissue. The data depicted in
Figure 2B shows that the FA values in rats with tumour
were always lower than the corresponding values of
the same regions in sham animals, indicating an evi-
dent loss of integrity in the brain of these GBM model.
The effect was lower for females in the core of the gli-
oma (Δ FA: −29.78% ± 0.43% for males vs. −28.55% ±
0.39% for females, P < 0.05) but notably higher in the
periphery (Δ FA: −18.00% ± 0.34% for males vs.
−26.37% ± 0.40% for females, P < 0.001). In Figure 3,
some representative maps of T1W, T2W, MTR, MD
and FA are shown for each group of animals.
Besides, perfusion studies were performed to assess the
cerebral integrity of the structure and function of the mi-
crovasculature which developed with angiogenic processes
in the glioma models. We used the dynamic susceptibility
contrast technique consistent in the acquisition of very
rapid images before, during and after the administration
of a bolus of Gd-DTPA to capture the microscopic mag-
netic susceptibility gradients generated in the first passage
of the agent through the capillaries in the brain. Consider-
ing that the arterial input function was not possible to be
determined in the experiment, data were normalized to an
apparently healthy brain region distant from the lesion.
Figure 4 shows the relative CBV (panel A) and MTT
(panel B) values measured in the glioma region, when
compared to an equivalent area in the control groups.
CBV values experienced a significant increase in both
genders, but the difference was more accentuated in male
rats (Δ CBV: 77.11% ± 2.75% vs. 61.03% ± 3.46%, P < 0.05).
The same behaviour was detected in the regional CBF de-
terminations (data not shown). In the case of MTT, there
was an increase in males, while a decrease was measured
for female rats (Δ MTT: 15.46% ± 0.35% vs. −2.06% ±
0.35%, P < 0.001).
The absolute MRI parameters (mean value and standard
error) collected in the four experimental groups (males
with tumour, females with tumour, males sham and
females sham) are presented in Table 1 (tumoural core)
and Table 2 (periphery of the tumour).
To conclude the MR analysis, we performed in vivo
volume-selected spectra in pathological and control
animals, which generated the results presented in
Figure 2 Results from diffusion tensor in the study of gender influence in a glioblastoma rat model. (A) Variation of MD values, as a
percentage, assessed in two brain regions (core and periphery of the tumour) of pathological rats related to the equivalent ones in sham animals.
(B) FA data in the same areas and condition. Unpaired t test analysis was performed on the data by comparing both genders in the same area.
Statistically significant differences are indicated in the columns, where *P < 0.05 and ***P < 0.001.
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images of a glioma-bearing rat (A) and a control rat (B)
and the corresponding spectra. Panel C indicates the
percentage of variation of different compounds in the
tumour related to the same region in sham animals.
Metabolites such as glycerophosphorylcholine + phospho-
choline (GPC + PCh) presented an increase in both sexes,
while phosphocreatine + creatine (PCr + Cr) showed a
decrease, but neither GPC+ PCh nor PCr + Cr presented
significant differences when the males were compared with
females (data are presented in Table 3).
Nevertheless, N-acetylaspartic acid (NAA) levels had an
overall decrease, with this decay being more accentuated
in males (−49.9 ± 14.5 vs. −11.6 ± 2.1, P < 0.001). Taurine
(Tau) increased in both sexes, being the effect higher for
females (41.2 ± 8.2 vs. 84.7 ± 16.9, P < 0.05). Myo-inositol
(Ins even experienced a different behaviour depending on
the animal gender. It suffered a notable increase in
females but a decrease in male rats (62.4 ± 6.2 vs. −16.0 ±
4.2, P < 0.0001).
Metabolic and motor activity
The results obtained from motor analysis test did not yield
significant differences, either between genders or between
pathologic and healthy animals. The assessment of water
and food intake was also similar between the experimental
groups (data not shown). Nevertheless, the respiratory
exchange rate, which measures the energy metabolism of
the animals, declined in tumour-bearing animals when
compared to the healthy controls. Once again, the RER
decrease was dependent on the gender of the animal,
being emphasized between day (−4.85 ± 0.24 for males vs.
−1.22 ± 0.09 for females, P < 0.01) and night (−4.11 ± 0.21
for males vs. −1.99 ± 0.14 for females, P < 0.01). This dif-
ference was superior for males during the light period and
for females at darkness (data shown in Figure 6).Postmortem analysis
Finally, excised gliomas and equivalent healthy brain re-
gions from the control rats were analysed. The peripheral
glioma marker GFAP was increased in the tumoural ani-
mals (Figure 7) and significantly higher in the male group
compared to the females (38.04 ± 7.22 vs. 2.25 ± 0.03, P <
0.01). Blood-brain barrier integrity was assessed by meas-
uring Evans blue-albumin extravasation. In diseased ani-
mals, the BBB permeability was also larger in males than
in female rats (39. 43 ± 3.94 vs. 15.19 ± 1.52, P < 0.05).
In order to analyse the role of glutamine and glutam-
ate in glioma development related to the animal gender
and because these two metabolites are difficult to dis-
tinguish an isolate in vivo with MRS, we measured the
tissue concentration of Glu and Gln by HPLC in tu-
mours and control regions. Both Gln and Glu concen-
tration was notably increased in male glioma related to
sham (15.6% ± 1.6% Gln, 8.5% ± 0.9% Glu). In contrast,
both metabolites only experienced a slight increase for
female animals (3.0% ± 0.2% Gln, 0.25% ± 0.01% Glu).
In both cases, differences between males and females
were statistically significant (P < 0.0001 for Gln and P <
0.001 for Glu).
Discussion
In the present work, we performed a multimodal ap-
proach in order to assess whether gender influences the
development of the glioblastoma by using the C6 glioma
model developed in Wistar rats. We carried out an
in vivo multiparametric analysis of the animals by using
magnetic resonance imaging and spectroscopy. The de-
termination of MR parameters linked to physiological
features in the tissues [38-40] allowed us to identify im-
portant physiopathological sexual dimorphism in this
model of brain cancer. We also evaluated the basal en-
ergy metabolism and neurological alterations (expressed
Figure 3 MR images of one rat from every group in one slice. First row images correspond to T2W acquisitions in which tumours can be
detected as hyperintense areas. Second row shows T1W images, after the administration of a contrast medium that enhanced the tumoural
region. Third, fourth and fifth rows present colour-base maps of MTR (%), MD (μm2/s) and FA measurements respectively, depicted always with
dark blue those with lower values in the corresponding parameter.
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postmortem analysis to measure the glioblastoma
biomarker GFAP to assess the BBB integrity and to de-
termine the content of Gln and Glu in the tumours.
Magnetization transfer contrast imaging is based on
the contribution to the MR signal of the two different
water pools present in the tissues, corresponding to the
free water or mobile molecules (with a long T2) and the
less mobile protons bounded to macromolecules and
membranes (with a short T2) [41]. This phenomenon in
a tumour is related to the cell proliferative rate, inflam-
mation and oedematous processes, and necrosis [24,39].
As the density of cells increases, the amount of mem-
brane macromolecules becomes higher and so the water
molecules bounded to them. In our studies, the MTR in
the glioma-bearing rats relative to the sham groupsnotably decreased in the core of the tumour presumably
due to the presence of necrotic areas without any signifi-
cant difference between genders. Nevertheless, the per-
centage of MTR was higher in the tumour periphery,
suggesting that this area is the most proliferative region.
This effect was sex dependent, being higher in males
than in females. The results point to a higher prolifera-
tion rate in gliomas on male animals and thus an
increased malignant potential of the tumoural evolution
in this sex.
These assumptions were supported by the results ob-
tained from diffusion studies. The values of MD and FA
measured are also dependent on the cerebral microstruc-
ture including cellularity, extracellular tortuosity and swell-
ing or shrinking cell processes associated with the presence
of inflammation and vasogenic or cytotoxic oedema
Figure 4 Results obtained from perfusion in the study of
gender influence in a glioblastoma rat model. (A) Variation in
the relative CBV values, as a percentage, in the tumour of
pathological rats related to the equivalent ones in sham animals.
(B) Relative MTT values in the same region and condition. Unpaired
t test analysis was performed on the data by comparing both
genders in the same area. Statistically significant differences are
indicated in the columns, where *P < 0.05 and ***P < 0.001.
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http://www.ejnmmires.com/content/4/1/44[38,42]. Many studies demonstrate that a decrease of the
MD indicates that the movement of the water molecules
across the extracellular matrix was hindered due to a
higher cell density in the core region of the tumour com-
pared with the surrounding tissue. The effect was major in
males in accordance with magnetization transfer results
that suggest a higher cell proliferation rate for this sex.
However, variation of the MD values experienced an
increase in the core of the tumour compared with sham
animals in both sexes, suggesting the presence of necrosis
and/or vasogenic oedema. This phenomenon was also not-
ably superior in male rats than in females. A higher disrup-
tion of the BBB in glioma-bearing males was further
confirmed by measuring the extravasation of Evans blue,
suggesting a strong vasogenic oedema in this group. On
the other hand, FA values of pathological compared withTable 1 MRI data measured in the core of the tumour in ever
Parameter Male/tumour Female/tu
MTR (%) 14.29 ± 0.35 13.02 ± 0.0
MD (μm2/s) 1,200 ± 9 1,120 ± 5
FA 0.244 ± 0.002 0.224 ± 0.0
CBV (a.u.) 1.44 ± 0.03 1.55 ± 0.04
CBF (a.u.) 1.56 ± 0.03 1.55 ± 0.03
MTT (a.u.) 1.077 ± 0.009 0.934 ± 0.0
Perfusion images were analysed in the whole glioma. MRI, magnetic resonance ima
anisotropy; CBV, cerebral blood volume; CBF, cerebral blood flow; MTT, mean transihealthy animals were decreased in both regions as ex-
pected due to the loss of integrity in the brain micro-
structure as the tumour grows. This decrease was again
higher for males in the core but unexpectedly lower in
the tumour periphery. Although we have to dip in that,
maybe one of two phenomena, or both, is taking place
to yield this result. On one side, a better organization
of this tumoural region was reported by Zhang et al.
who found high diffusion directionality in the rims of
rat brain gliomas demonstrating the existence of an ele-
vated level of organization at the cellular level inside
these tumours [43]. This study was performed using
only males, and in view of our results, we can anticipate
that this effect would have at least less significance in
females in our GBM model. On the other hand, Lope-
Piedrafita et al. published a longitudinal diffusion ten-
sor imaging (DTI) analysis of C6 glioma rats showing
high FA values in the brain tissue surrounding the
tumour due the great glioma proliferation rate [44]. In
that case, studies were carried out in females, and
because the FA value in our pathological animals was
higher for males, the lower decrease of FA in glioma
for this gender compared to sham animals suggests a
minor aggressiveness in glioma of females.
Clinical perfusion MRI measurements are currently
recognized as one of the most powerful tools to assess
tumour vascularization and response to treatment
through the evaluation of haemodynamic parameters
[20]. While CBV can be considered an indicator of the
blood supplied to feed the lesion, MTT has to be taken
as a marker of the microvessel density and their aberrant
distribution in the tissue [40]. In this line, PW imaging
gives crucial information related to angiogenic events in
the glioma and viability of the vessels in the brain. In
our study, glioma-bearing animals were depicted to have
higher values of CBV compared with sham rats, and the
increase was significantly higher in male than in female
rats. This may be related to a different extension of
angiogenesis depending on the gender. Additionally,
MTT determinations showed a superior tortuosity and/
or density of vessels inside the glioma of male animals,y experimental group
mour Male/sham Female/sham
7 20.13 ± 0.23 18.57 ± 0.22
1,028 ± 4 988 ± 5
01 0.348 ± 0.002 0.314 ± 0.002
0.81 ± 0.04 0.97 ± 0.03
0.81 ± 0.04 0.97 ± 0.03
06 0.933 ± 0.011 0.953 ± 0.010
ging; MTR, magnetization transfer ratio; MD, mean diffusivity; FA, fractional
t time.
Table 2 MRI data measured in the periphery of the tumour in every experimental group
Parameter Male/tumour Female/tumour Male/sham Female/sham
MTR (%) 22.00 ± 0.16 19.60 ± 0.12 20.10 ± 0.20 18.14 ± 0.22
MD (μm2/s) 963 ± 5 955 ± 4 1,036 ± 5 1,006 ± 5
FA 0.279 ± 0.002 0.232 ± 0.001 0.340 ± 0.002 0.316 ± 0.002
MRI, magnetic resonance imaging; MTR, magnetization transfer ratio; MD, mean diffusivity; FA, fractional anisotropy.
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http://www.ejnmmires.com/content/4/1/44which together with previous parameters corroborates a
higher malignancy in males.
Molecular results from in vivo MR spectra pointed
some interesting features. The expected and reported
decrease in NAA levels in glioma animals caused by the
development of the C6 glioma [45] was significantly
higher in male animals, in concordance with previous
results that indicate a poor prognosis of the tumour in
this sex. The use of total choline as a malignancy
marker in clinical routine is widely extended nowadays, by
using not only MRS approaches but also different imaging
techniques [46]. In our studies, choline-containing com-
pounds probably increased as a consequence of theFigure 5 Results from in vivo spectra in the study of gender influence
T2W images and the selected region for acquiring the spectrum in a rat wi
(C) The percentage of variation in the concentration of several metabolites
test analysis was performed on the data by comparing both genders in the
columns, where *P < 0.05, ***P < 0.001 and ****P < 0.0001. Ins, myo-inosito
phosphocreatine + creatine; Tau, taurine; NAA, N-acetylaspartic acid.exacerbated turnover of cell membranes due to the ag-
gressiveness of these tumours [47], but without differences
between sexes. Also, the decrease in creatine-containing
compounds occurred without gender differences. In con-
trast, significant differences were found in the measure-
ment of Ins and Tau, highly dependent on the animal sex.
Concentration of myo-inositol was notably increased in
females and decreased in males. It is reported that this
metabolite is related to the grading of gliomas, being the
lower level of Ino as an indicator of higher malignancy of
the tumour [48]. In our case, we can assume a lower ag-
gressive or malignant behaviour for female rats with gli-
oma, in which Ins increased. Nevertheless, it is importantin a glioblastoma rat model. Upper panel depicts both examples of
th (A) and without (B) tumour and the corresponding fitted spectra.
detected in tumour related to sham animals in both sexes. Unpaired t
same area. Statistically significant differences are indicated in the
l; GPC + PCH, glycerophosphorylcholine + phosphocholine; PCr + Cr,
Table 3 Magnetic resonance spectroscopy in vivo results
Ins CPC + PCh PCr + Cr Tau NAA
Male −16.0 ± 4.2 19.8 ± 3.6 −35.3 ± 6.7 41.2 ± 8.2 −49.9 ± 14.5
Female 62.4 ± 6.2 23.8 ± 1.2 −39.5 ± 7.9 84.7 ± 16.9 −11.6 ± 2.1
The values express the percentage of variation in the metabolite concentration measured in the glioma of pathological individuals related to an analogous
healthy region in brain of sham animals for every sex Ins, myo-inositol; GPC + PCH, glycerophosphorylcholine + phosphocholine; PCr + Cr, phosphocreatine +
creatine; Tau, taurine; NAA, N-acetylaspartic acid.
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http://www.ejnmmires.com/content/4/1/44to mention here that Ino signal usually overlaps with Gly
resonance, making them hardly distinguishable from
in vivo spectra, especially at short TE values as our case is.
Gly has been reported to be increased in GBM [49], so we
could not affirm that an increase in this metabolite is not
contributing to the high intensity signal in female rats. But
because experimental results point to a major malignancy
in males, we favour to think that the increase in Gly would
not be higher for females and what we are measuring in
the MRS signal at approximately 3.5 ppm is predomin-
ately the Ins contribution. Testing taurine concentration,
we checked that this compound level augmented in all gli-
oma animals, but the effect was significantly superior for
females. This might be due to specific functions of this
amino acid, being either protective or involved in the pro-
liferation of cells. Tau is increased in malignant gliomas in
correlation to the stage of cell proliferation and the pres-
ence of oedema [50]. According to that and the MRIFigure 6 Results of energy metabolism in the study of gender
influence in glioblastoma rat model. The graphic shows the
obtained RER values. Data are divided in two circadian cycles (day
and night). Unpaired t test analysis was performed on the data by
comparing both genders in the same area. Statistically significant
differences are indicated in the columns, where **P < 0.01 and
***P < 0.001.results, we would expect a higher Tau increase in males
than in females, so we could also speculate that the pres-
ence of high taurine in the tumours could be playing a
protective effect in female rats. This is in concordance
with reported studies that indicate that taurine MRS signal
is an apoptotic biomarker that is independent of tumour
necrotic status [51]. In any case, a better understanding of
the role of Tau in the development of this glioma model
needs further studies. Finally, in the assessment of glutam-
ate and glutamine, the individual contribution was not
possible to isolate from 1H spectra, and even the total
Glu + Gln peak can be contaminated with gamma-
aminobutyric acid (GABA) resonances. So, we performed
a postmortem analysis of tumour with HPLC to determine
the concentration of each compound establishing that glu-
tamine and glutamate, specially the former, were increased
in glioma male groups, while there was almost no vari-
ation measured for female rats. In terms of metabolicFigure 7 Results from postmortem analysis of plasma and
tumoural tissue in the study of gender influence. Left bars
correspond to the GFPA determination in rats measured as a
percentage of the same value in sham animals. Right bars show the
values in the measurement of the Evans blue accumulation.
Unpaired t test analysis was performed on the data by comparing
both genders in the same area. Statistically significant differences are
indicated in the columns, where *P < 0.05 and **P < 0.01.
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http://www.ejnmmires.com/content/4/1/44function, Gln is strongly involved in anabolic pathways. In
particular, through aspartate, Gln is essential for the syn-
thesis of purine and pyrimidine bases as a carbon and ni-
trogen donor [52]. This phenomenon seems to be
important for the adaptation of tumours in the transition
from aerobic to anaerobic state [53]. Furthermore, it has
been hypothesized that Gln serves as an energy fuel
through glutaminolysis, which seems to be a prerequisite
for tumour cell growth [54]. The reason why glutamine is
not significantly increased in the female tumour group in
our rat model is unknown and deserves future studies tak-
ing also into account that gender differences have been re-
ported in healthy subjects in some brain areas [55]. These
results can suggest the intriguing possibility that metabol-
ism of brain tumour cells might be different depending on
sex as shown in healthy subjects [56] or patients with Alz-
heimer' disease [57]. Besides, gender differences have been
described in neuronal metabolism studied in in vitro
model. In primary cell culture, neurons from males
undergo autophagy and die faster, whereas neurons from
females mobilize fatty acids, accumulate triglycerides,
form lipid droplets and survive longer [58]. Sharma et al.
also found that neuronal death pathways following
hypoxia-ischemia are sexually dimorphic [59].
As far as we know, this is the first study on gender in-
fluence on the motor and metabolic activity in a rat
model of GBM using a multichannel system with indi-
vidual cages. The RER factor by circadian cycles (a linear
indicator of energy metabolism activity) was decreased
in tumour-bearing animals compared with the control
animals, both in female and in male rats, but this decay
was always higher for the latter and the difference was
statistically significant both at light and at darkness cy-
cles. A lower RER value shows a greater fat metabolism,
whereas an increased RER should indicate a greater
carbohydrate metabolism. Previous studies reported that
during low to moderate intensity exercise, women main-
tain a lower RER when compared to men, being the pre-
sented results consistent with these findings of a sex
difference in basal activity levels [60,61].
To end, we measured the putative peripheral GBM
biomarker that is highly specific for cells with astrocytic
differentiation and is widely used as a reliable marker in
the immunohistochemical diagnosis and differentiation
of brain [62]. In human studies, it has been shown that
the expression of GFAP is increased in the serum of pa-
tients with glioblastomas compared to other groups of
patients with neural tumours and healthy ones [29,63].
We found an increased expression of serum GFAP more
prominent in glioma-bearing male rats. Several physio-
pathological mechanisms may explain increased GFAP
levels in serum of GBM patients, including disruption of
BBB and/or the extent of tumour angiogenesis or
tumour necrosis. The fact that female tumour rats didnot show a higher value of this parameter suggests that
the increase in BBB permeability in the glioma of male
rats, as has been exposed previously, might likely con-
tribute to the gender difference in GFAP, although other
mechanisms cannot be ruled out and needs further
investigation.
Conclusions
Brain tumourigenesis and growth assessed in C6 glio-
blastoma animal model is different between male and fe-
male rats. These differences encompass several MR
parameters related to structural, functional and molecu-
lar features of the tumour. Most of them presented sex-
ual dimorphism suggesting a higher malignancy and
aggressiveness for male gender. In any case, the results
hold substantial differences in the tumour behaviour for
both genders. There were specially detected alterations
in values linked to proliferation rate, inflammatory and/
or oedematous processes and blood-brain barrier integ-
rity. These MR parameters can be used as surrogate
markers of the disease progression and validation of tar-
geted therapies. Since relevant sex differences have
emerged in this study, we suggest that the gender should
be always considered in those studies aimed at investi-
gating tumour behaviour (growth, angiogenesis, inflam-
mation, proliferation rate and metabolism) and new
pharmacological treatment in glioblastoma research.
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